Advertisement


Heather Wakelee, MD, on NSCLC: IMpower010 Survival Results After Long-Term Follow-up of Atezolizumab vs Best Supportive Care

2024 ASCO Annual Meeting

Advertisement

Heather Wakelee, MD, of Stanford University Medical Center, discusses phase III findings showing that the disease-free survival benefit with adjuvant atezolizumab continues to translate into a positive overall survival trend vs best supportive care in patients with stage II–IIIA non–small cell lung cancer (NSCLC). These results further support the use of adjuvant atezolizumab in PD-L1–selected populations, according to Dr. Wakelee (LBA8035).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
IMpower010, which looked at adjuvant atezolizumab for patients with completely resected early stage non-small cell lung cancer, we presented the long-term final disease-free survival as well as the second interim overall survival data, now with over 60 months of follow-up. The study had a complex hierarchical statistical design such that first group were those with PD-L1 expression stage 2 to 3A, next group, all stage 2 to 3A, then all comers, including about 12% of patients with 1B, and only if all three of those were met could we formally test overall survival. As was seen in the first interim analysis, the second interim now with the final disease-free survival in that first group with PD-L1 expression stage 2 to 3A remains robust with a hazard ratio of 0.7, translating into nearly a 30-month difference in disease-free survival. In the second group, when we look at all stage 2 to 3A, continue to see a disease-free survival benefit, which does reach statistical significance, hazard ratio of 0.85. But when we bring in that stage 1B, that drops to... Sorry, that was 0.83. ... 0.85, when we bring in that other group, no longer statistically significant. So overall survival could not be formally tested, but we do continue to see this robust disease-free survival benefit, particularly in those with PD-L1 expression. And when we look at those with the highest PD-L1 expression, greater than 50%, that disease-free survival benefit hazard ratio was 0.48. We haven't reached the median for that group of patients. And, in that group, the overall survival hazard ratio was 0.47. However, we can't formally statistically test that because of the way the trial is designed. So in conclusion, when we look at this final disease-free survival result and second interim overall survival result from IMpower010, we do continue to see robust clinical benefit for patients who have gone through surgical resection with early stage lung cancer, stage 2 to 3A, where their tumor expresses PD-L1 expression. And we do believe this continues to be a very reasonable treatment option for that subgroup of patients where there is PD-L1 expression, particularly in those with the highest PD-L1 expression of greater than 50%.

Related Videos

Leukemia
Immunotherapy

Allison M. Winter, MD, on Richter Transformation: New Data on a CAR T-Cell Treatment

Allison M. Winter, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses real-world outcomes with lisocabtagene maraleucel in patients with Richter transformation, a difficult-to-treat population with a poor prognosis. Data from the Center for International Blood and Marrow Transplant Research showed this therapy provided clinical benefit with a high complete response rate (Abstract 7010).

Leukemia

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Update on BTK Inhibitors

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses a network meta-analysis showing that zanubrutinib appears to be the most efficacious Bruton’s tyrosine kinase (BTK) inhibitor for patients with high-risk relapsed or refractory chronic lymphocytic leukemia. It offers delayed disease progression and favorable survival and response, compared with alternative BTK inhibitors (Abstract 7048).

 

Bladder Cancer

Jonathan E. Rosenberg, MD, and Thomas Powles, MD, PhD, on Urothelial Carcinoma: Expert Commentary on Two Key Abstracts

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, discuss phase III findings from two studies: the first, investigating enfortumab vedotin-ejfv and pembrolizumab vs platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic urothelial cancer; and the second, looking at nivolumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone in patients with lymph node–only metastatic disease enrolled in the CheckMate 901 trial (Abstracts 4581 and 4565).

Breast Cancer

Ana C. Garrido-Castro, MD, on Metastatic Breast Cancer: Trial Update on Sacituzumab Govitecan With or Without Pembrolizumab

Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, reports the results from the phase II SACI-IO trial in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who received sacituzumab govitecan-hziy with or without pembrolizumab (LBA1004).

Prostate Cancer
Genomics/Genetics

Alicia Morgans, MD, MPH, and Susan Halabi, PhD, on Prostate Cancer: New Findings on Classifying Patients Into Risk Groups

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Susan Halabi, PhD, of the Duke Cancer Institute and Duke University School of Medicine, discuss a clinical-genetic model that identified novel circulating tumor DNA alterations that are prognostic of overall survival and may help to classify patients with metastatic castration-resistant prostate cancer into risk groups useful for selecting trial participants (Abstract 5007).

Advertisement

Advertisement




Advertisement